GlassScriptPhysician profile
Sara Julazadeh
NPI 1952592768
$6,474.68
in general payments reported to CMS, 2019-2025
24 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $223 · 2021: $815 · 2022: $1,490 · 2023: $581 · 2024: $1,716 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552 · Entertainment: $23.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.34 |
| Entertainment | $23.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,373.80 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $609.43 | 2022-2025 | Miebo, Xiidra, Envista Envy Iol |
| Johnson & Johnson Surgical Vision, INC. | $517.30 | 2020-2025 | Tecnis Simplicity |
| Oyster Point Pharma, INC. | $468.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $452.61 | 2021-2025 | Rocklatan |
| Abbvie INC. | $400.06 | 2022-2025 | |
| Rxsight INC | $399.82 | 2022-2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $301.93 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $301.86 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $258.75 | 2020-2022 | |
| Harrow Eye, LLC | $255.51 | 2024-2025 | Vevye, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.31 | 2019-2021 | |
| Dompe US, INC. | $184.23 | 2021-2022 | |
| Sight Sciences, INC. | $160.15 | 2023 | Tearcare System |
| Aerie Pharmaceuticals, INC. | $119.96 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.53 | 2019 | |
| Allergan, INC. | $71.94 | 2019-2021 | |
| Horizon Therapeutics Plc | $68.66 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $67.47 | 2024-2025 | Xdemvy |
| Amgen INC. | $63.17 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $59.35 | 2019-2025 | |
| Optos, INC. | $23.31 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $18.99 | 2024 | Photrexa |
| Shire North American Group INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Julazadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.